Literature DB >> 671237

Pharmacokinetics of intravenous erythromycin.

P G Welling, W A Craig.   

Abstract

Erythromycin pharmacokinetics were examined following intravenous infusion to male subjects. The biological half-life of erythromycin in serum was 2 hr in individuals with normal renal function. The half-life varied in cases of reduced renal function, with values of 3.9 and 7.0 hr occurring in two subjects with severe renal impairment. Postinfusion serum erythromycin levels were adequately described by two-compartment model kinetics, and values for the distribution volume of the central compartment and the overall distribution are described. Estimated erythromycin distribution volumes in normal individuals may facilitate calculation of absorption efficiencies of erythromycin and its salts after oral doses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 671237     DOI: 10.1002/jps.2600670809

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  14 in total

Review 1.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

3.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

4.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

5.  Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

Authors:  J Barre; A Mallat; J Rosenbaum; L Deforges; G Houin; D Dhumeaux; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

6.  Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin.

Authors:  A A Somogyi; F Bochner; D Hetzel; D B Williams
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

7.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

8.  Disposition of roxithromycin in patients with normal and severely impaired renal function.

Authors:  C E Halstenson; J A Opsahl; M H Schwenk; J M Kovarik; S K Puri; I Ho; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

9.  Should erythromycin dose be altered in haemodialysis patients?

Authors:  A Iliopoulou; K Downey; D M Chaput de Saintonge; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.